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ABSTRACT
Elective root replacement in Marfan syndrome has
improved life expectancy in affected patients. Three
forms of surgery are now available: total root
replacement (TRR) with a valved conduit, valve sparing
root replacement (VSRR) and personalised external aortic
root support (PEARS) with a macroporous mesh sleeve.
TRR can be performed irrespective of aortic dimensions
and a mechanical replacement valve is a secure and
near certain means of correcting aortic valve
regurgitation but has thromboembolic and bleeding
risks. VSRR offers freedom from anticoagulation and
attendant risks of bleeding but reoperation for aortic
regurgitation runs at 1.3% per annum. A prospective
multi-institutional study has found this to be an
underestimate of the true rate of valve-related adverse
events. PEARS conserves the aortic root anatomy and
optimises the chance of maintaining valve function but
average follow-up is under 5 years and so the long-term
results are yet to be determined. Patients are on average
in their 30s and so the cumulative lifetime need for
reoperation, and of any valve-related complications, are
consequently substantial. With lowering surgical risk of
prophylactic root replacement, the threshold for
intervention has reduced progressively over 30 years to
4.5 cm and so an increasing number of patients who are
not destined to have a dissection are now having root
replacement. In evaluation of these three forms of
surgery, the number needed to treat to prevent
dissection and the balance of net benefit and harm in
future patients must be considered.
Aortic dissection is by far the commonest cause of
death in the natural history of Marfan syndrome and
other genetically defined aortopathies (figure 1).
When there is an aortic root aneurysm, prophylactic
surgery on the aortic root intended to prevent aortic
dissection is the most important life prolonging treat-
ment for individuals with these conditions and will
therefore be given the most attention within the lim-
itations of this clinical review.
Among the total number of patients with root
aneurysms, those with a diagnosis of Marfan syn-
drome dominate the younger age range but they are
nevertheless a minority of all patients with ascending
aortic aneurysm1 (figure 2). They are prone to acute
dissection and prior to the introduction of prophylac-
tic root replacement this was the cause of death in
two-thirds of all patients and often at a young age.2–4
Detection, diagnosis, monitoring and prophylactic
surgery are believed to have dramatically reduced
deaths from dissection and to have resulted in
increased longevity in these patients.
THE APPROACH TO PREVENTION OF ACUTE
ASCENDING AORTIC DISSECTION IN MARFAN
SYNDROME
The threshold for elective intervention and the
NNtT
The genetic aortopathies are of their nature usually
clustered in known affected families. These families
are increasingly well informed and highly moti-
vated to have their relatives and children assessed
and to attend for echo measurements. In the
current era, the occurrence of acute dissection of
the ascending aorta in patients such as these will
raise the question whether this was a failure of
diagnosis, surveillance or decision making on the
part of medical services.
In the context of aortic root surgery, if the
threshold is set sufficiently low to minimise the risk
of acute dissection, the population selected to have
prophylactic surgery must inevitably include
patients not destined to have AAD and who would
have died with an intact ascending aorta.
Recognition of this fact leads to a need to estimate
an important but at present unavailable statistic:
the number needed to treat (NNtT). For patients
with aortic root aneurysm at any given threshold
for intervention, we should ideally know the NNtT
to prevent a dissection and the NNtT to save a life.
Consider as an example carotid endarterectomy
which is performed to prevent stroke. For patients
with 70%–99% carotid artery stenosis and who
have had a transient ischaemic attack (the highest
risk group for stroke), the NNtT is six, rising to 24
for 50%–69% stenosis.i These data are based on
randomised trials. What is the NNtT at present day
thresholds for root replacement? Because we inter-
vene to prevent dissection, there are no contempor-
ary data or prospective studies to guide us. As we
have lowered the size threshold for intervention,
the NNtT has necessarily increased.
PROPHYLACTIC SURGERY ON THE AORTIC
ROOT
The most common form of aortic root aneurysm is
that seen in Marfan syndrome. We recognise a char-
acteristic morphology originating and
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predominately affecting the sinuses of Valsalva, in which the
expansion of the aorta includes the wall of the sinuses proximal
to the coronary orifices (figure 3). In current practice, this form
of aneurysm is amenable to confident echo diagnosis.
More complete morphological evaluation and measurement
are readily achieved by either MRI or CT. In current practice,
we recognise patients at risk of AAD by an enlarging aneurysm
of the aortic root particularly with a family history of dissection.
Replacement of the aortic root removes that specific risk. Distal
segments of the aorta remain prone to aneurysmal dilatation,
dissection and rupture.
The shape of the aortic root merits close attention (figure 4).
The portion of the aortic wall proximal to the coronary orifices
is characteristically elongated. This is not seen in ascending
aortic aneurysms associated with bicuspid aortic valve disease
for example. The diameter at the level of closure of the aortic
leaflets and its rate of change are the measurements used to
make recommendations to the patient with respect to timing of
aortic root surgery. Increasingly, the clinical diagnosis will be
confirmed and augmented by knowledge of an individual’s
genome5 but this should not distract attention from the hazard
represented by the aortic root disease. We argue here that
patients with other aortopathies such as Ehlers–Danlos syn-
drome and Loeys–Dietz syndrome should generally be consid-
ered for aortic root surgery on similar imaging criteria, but in
the latter perhaps at smaller size.
Size threshold for prophylactic root replacement
Current ESC/EACTS guidelines for the management of valvular
heart disease state that, irrespective of the presence and severity of
aortic valve regurgitation, surgery should be considered in patients
with Marfan syndrome with risk factors (family history of dissec-
tion, size increase 2 mm/year in repeated examinations) who have
aortic root disease with a maximum ascending aortic diameter of
≥45 mm (Class IIa, Level C evidence).6 The size criterion has
come down from 60 mm, through 55 and 50 mm7–10 to the
present recommendation of 45 mm.6 An increasing number of
patients having root replacement were not destined to ever have
have an AAD, and hence our emphasis on needing to know the
NNtT.
THE CHOICE OF OPERATIONS
Total root replacement
The current form of total root replacement (TRR) is with a
conduit of low porosity woven Dacron incorporating a mechan-
ical valve, usually bi-leaflet, with the coronary arteries anasto-
mosed to the tube graft. There is the option of incorporating a
tissue valve.11 This surgery has come a long way since the first
operation by Bentall and De Bono in 1968.12 It is now a low
risk, reproducible operation.
Figure 1 Acute aortic dissection in a man in his 50s from a family with Marfan syndrome and a history of several dissections and root
replacements. One of the kidneys is not being perfused.
Figure 2 Relationship between age and the aetiology of aneurysms
of the ascending aorta.1
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Valve sparing root replacement
It was the desire to spare patients the consequences of mechanical
valve replacement that led Yacoub et al13 14 and David et al15–17
to separately devise valve sparing root replacement (VSRR)
operations, respectively, remodelling and reimplantation proce-
dures. These are technically more demanding than TRR and
revert to the ‘workmanship of risk’ where the surgeon has to
make a series of judgements and unique adjustments typifying
the craftsmanship of ‘free hand’ surgery. After 10 years of
follow-up, the remodelling approach failed more often because
the aortic annulus is not stabilised. In contrast, the results of the
David procedure more often remain satisfactory to 15 years. In
the last 10 years, there has been a growth of a variety of leaflet
techniques and a classification system for aortic regurgitation
based on the principles of Carpentier’s classification of mitral
regurgitation, which provides a universal vocabulary for commu-
nication. The dissemination of aortic valve repair has been
slower than that for the mitral valve for two reasons. First, the
surgeon’s view of the aortic valve is from the outflow side
making it impossible to visually assess and test the valve in its
pressurised state and second the gradual recognition of the
importance of two distinct structures in the aortic root, the
ventriculo-aortic junction and the sino-tubular junction.
Personalised external aortic root support
In 2004, the first of a new form of operation was reported
intended to prevent further growth in root aneurysms.18 This is
quite different in concept from the two established procedures
and is intended to be a prophylactic procedure. It has been evalu-
ated in patients on average at an earlier stage in the natural
history of MFS, in adults with aortic roots measuring between 40
and 50 mm, without aortic regurgitation. The patient’s own
images are used to create a faithful copy of the aorta by computer
aided design which is then made into a physical copy by ‘3D
printing’.19 A macroporous fabric sleeve is then made which is
placed around the aorta, including the segment proximal to the
coronary arteries, down the aorto-ventricular junction (figure 5).
This swings the pendulum towards the ‘workmanship of cer-
tainty’: the surgeon is provided with a device which is made to
measure for that individual’s aorta and which will hold the
aortic root at its existing shape and size. The process allows
for a measured reduction in its diameter20 (figure 6). A formal
Figure 3 Cardiac magnetic
resonance images. Dark blood
spin-echo image (left) and a diastolic
frame from complete cine acquisition
(right) of severe aortic root dilatation
of typical Marfan morphology with
type A dissection and functional severe
eccentric AR and LV dilatation. The
aortic root diameter is 8 cm.
Figure 4 Aortic roots with the characteristic morphology and distal displacement of the coronary orifices but without gross enlargement. The CT
image (left) is a volume rendered image of an ECG-gated scan of the thoracic aorta. The CMR image (right) is a thin section from a 3D steady-state
in free precession sequence acquired in the left anterior oblique projection.
Treasure T, et al. Heart 2014;100:1571–1576. doi:10.1136/heartjnl-2013-305132 1573
Review
group.bmj.com on December 10, 2014 - Published by http://heart.bmj.com/Downloaded from 
evaluation of whether aortic regurgitation can be reduced or
eliminated is yet to be done but has been noted anecdotally.
The fabric, unlike the vascular grafts used in root replace-
ment, is incorporated histologically creating a composite aortic
wall which does not dilate further.21 22
Of its nature, this is not an option for patients who present
with aortic dissection. It is unlikely to have a place in reopera-
tion after aortic root surgery but could be an adjunct to protect
other segments of the aorta. Personalised external aortic root
support (PEARS) has been used as part of complex surgery in
adult congenital heart disease and in combination with coronary
artery surgery.
COMPARATIVE ANALYSIS OF THE THREE PROPHYLACTIC
OPERATIONS
Procedural burden of care
The Aortic Valve Operative Outcomes in Marfan Patients
(AVOOMP) study group provides prospectively collected data
on 239 patients having root replacement between 2005 and
2010.23 For TRR (N=77) and VSRR (N=239), the median car-
diopulmonary bypass times were 152 and 194 min and cross
clamp times were 115 and 156 min. Circulatory arrest was used
in 29% and 20%, respectively. It should be noted that the rela-
tively few TRR operations were in older and higher risk patients
reflecting preference for valve sparing surgery among these sur-
geons. In units where valve replacement is the usual and pre-
ferred operation, operative times for TRR are likely to be
shorter. PEARS is routinely done without cardiopulmonary
bypass, myocardial ischaemia or circulatory arrest. These pro-
cedural differences have been quantified in a comparative
study.24
Risk of perioperative death
In contemporary practice, in experienced units, the mortality
for elective TRR in these patients, whose average age is mid-
thirties, is under 1% and some teams now report that they have
had no deaths for some years. In the AVOOMP study, 30-day
mortality was 1/77 for TRR (1.3%; 95% CIs 0.06% to 13%)
and 1/239 for VSRR (0.04%; 0.01% to 2%).23 The 34th
patient of 41 intended to have PEARS for Marfan syndrome
died 5 days after surgery following an operative injury to the
left main coronary artery (1/41, 2.4%; 0.1% to 13%). He had
severe pectus excavatum.
Intention to treat and actual treatment
In the AVOOMP study,23 in six patients (6/239; 2.5%) there was
a problem with sparing the aortic valve resulting in conversion
to TRR with a composite valved root replacement. This
outcome is usually not reported in clinical series of VSRR
which are based on completed treatment rather than intention
to treat analysis. Conversion from intended VSRR to TRR is
generally more frequent than the AVOOMP rate of 1:40, par-
ticularly in small series and less experienced hands.
Among the patients in the AVOOMP study, cumulative, all-
cause aortic valve dysfunction at 1 year root replacement was
recorded to be 23/219 (10.5%), of which were five intraopera-
tive cases that were converted to mechanical AVR, one case of
coronary artery kinking that required immediate reoperation
(<30 days), one case of coronary pseudo aneurysm repair
6 days postoperative and 16 cases of AR 2+ or greater (mea-
sured at 1 year postoperative). The total rate of major adverse
valve-related events (MAVRE) at 1 year was 35/222 (15%).
In the first year after operation, there was one further death
in the TRR group (1/77, endocarditis) and two valve-related
deaths in the VSRR patients (2/239). There was no significant
difference in mortality or major adverse event rates for TRR or
VSRR but the groups are not directly comparable and the
nature of complications differs.
There has been one late death with PEARS 4.5 years after
operation. The ascending aorta and the aortic valve were intact.
Subsequent valve-related events
With mechanical valve TRR, lifelong anticoagulation is manda-
tory and the long-term course with respect to the root replace-
ment surgery is dominated by the continuing hazard of
thrombotic events and anticoagulant-related bleeding. In a
meta-analysis of 972 patients, the combined event rate for these
complications was 0.7%.25 In the first year in the AVOOMP
study where data were collected prospectively by study protocol,
the thromboembolic and bleeding rates were recorded as 2/75
(2.7%) and 5/75 (6.6%), respectively.23
Figure 5 Personalised external aortic root support. BCA,
brachiocephalic artery; LCA, left coronary artery; RCA, right coronary
artery.
Figure 6 Aortic root diameter over a 20-year period in a woman with
Marfan syndrome; the diameter continued to enlarge during a first
pregnancy and thereafter to reach the accepted threshold of 45 mm.28
She requested referral for personalised external aortic root support
(PEARS). Her aortic dimensions were reduced as was seen in eight of
the first 10 PEARS operations.20
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Because the patients are in their mid-thirties on average, and
many of them are in their teens and twenties, the impact of life-
long anticoagulation on quality of life is for some patients, con-
siderable. It influences decisions about pregnancy, travel, work
and recreation. Avoidance of these problems has been the driver
towards VSRR.
The major concern with VSRR is the possibility of subsequent
failure of the aortic valve. In both the meta-analysis by
Benedetto and colleagues25 and the single institution report
from Hannover,26 the re-intervention rate was 1.3% per annum.
This means that for a 20 year old expecting to live to 70 or
beyond, the likelihood of further surgery may be 65%. Even
this statistic understates the consequences of life affecting aortic
regurgitation without re-intervention. Among the VSRR patients
in the AVOOMP, the total rate of MAVRE was 65/225 (29%). It
is quite possible that mild degrees of aortic regurgitation can be
overlooked especially if the patient has a sinus tachycardia,
which will reduce the regurgitant fraction and will be well toler-
ated in young people.
At an average of over 4 years follow-up, there have been no
instances of new or worsening regurgitation with PEARS.
Effectiveness in preventing aneurysm and dissection
Replacement of the ascending aorta precludes dissection in that
segment of the aorta but not elsewhere. Although dissection has
not been seen to date, PEARS cannot abolish the risk of dissec-
tion. The aorta is held at its preoperative or slightly smaller size
so the major factor predisposing to dissection is obviated and
this is likely to diminish the risk. The evidence of incorporation
of the supporting mesh means that should dissection occur it
would not lead to intrapericardial rupture which is the proxim-
ate cause of death in acute aortic dissection and the incorpor-
ation of the mesh will provide a technically more secure aortic
wall at any subsequent operation than native Marfan aortic
tissue.
The vulnerable sites for false aneurysm formation after TRR
and VSRR are at suture lines, proximal and distal anastomosis
of the tube graft, and around the coronary arteries. None of
these sutured anastomoses are made in PEARS.
Availability of the three procedures
At present, PEARS is only available in a limited number of
centres; four units have performed this surgery to date. TRR
remains the commonest of the operations performed and is the
most generally applicable form of surgery because it can be
carried out irrespective of the size of the aorta or the degree of
aortic valve regurgitation. For elective operations in young
patients, the avoidance of lifelong anticoagulation and mechan-
ical aortic valve-related thromboembolic events and endocarditis
should be considered in referring patients for root replacement.
They should be advised of the relative risks and benefits of valve
sparing and valve replacing surgical alternatives.
SELECTION CRITERIA FOR TRR, VSRR AND PEARS
The recommended size criteria for intervention on the aortic
root to avert dissection are based on the risk of further waiting
balanced against the procedural risk of the surgery. The guid-
ance from the European Society of Cardiology and the
European Association for Cardio-Thoracic Surgery6 cites the
review in the Lancet from 20052 which in turn cites data from
1972. Better data are needed if we are to know the NNtT and if
we are to have comparative effectiveness data and cost-
effectiveness for these three surgical approaches.
The question has been revisited in a decision analysis but
unfortunately it gets us no further.27 The modellers had a
wealth of data to use for survival after root replacement but for
the critical estimate of survival without surgery they relied on
five experts. The authors concluded that the gain in operating
on an aorta of 5 cm diameter at the age of 20 is to increase life
expectancy from 71 to 73 years. In the model, the estimated
survival for patients with aortic root diameters of 6–7 cm was
68–69 years. This is very different to present beliefs about the
risk of aortic root aneurysm so the model lacks face validity. It
was of course an impossible question to answer. For example,
the probability of being alive tomorrow is almost certainly
better if you do not have your elective operation today so the
exercise was heavily dependent on how the question was under-
stood. These responses may have been informed by experience
but did not provide the sort of information on which to build a
robust mathematical model. What is more concerning is that
there is no evidence to suggest that they were challenged for
lack of face validity before publication.
DIFFERING CRITERIA FOR TRR, VSRR AND PEARS
TRR can be performed irrespective of aortic dimensions and
the replacement valve is a secure and near certain means of cor-
recting aortic valve regurgitation. A patient accepting lifelong
anticoagulation, but not wanting ever to have further surgery,
might choose this option.
In contrast, VSRR maintains normal physiology and freedom
from anticoagulation and its attendant risks of bleeding. Failure
to consistently achieve and maintain a competent aortic valve is
the downside and there is a high lifetime probability of signifi-
cant valve regurgitation leading to deteriorating function and/or
further surgery.
PEARS seeks to include the benefits of VSRR but as a lesser
procedure can be offered at smaller size and since it preserves
the size and configuration of the aortic root optimises the
chance of maintaining valve function. To date, there have been
no instances of more than trivial aortic regurgitation. Results are
too few and too early to know longer term outcomes.
As we seek to avoid any failure of our prophylactic policy,
there will be a tendency to operate at lower size. One can argue
for offering a valve sparing strategy at lower size in aortas such
as those in figure 4. At present, we do not know how these deci-
sions are made in clinical practice but it is likely that it is influ-
enced by the beliefs of relative risk of the cardiologist and the
technical preference of the surgeon, but it should also involve
the patient who should be fully informed of the choices
available.
The authors are actively seeking funding for a prospective
evaluation of the surgical options available. This is provisionally
called the Big Aortic Root Study. The tentative proposal is that
this will incorporate an observational design similar to
AVOOMP study23 with a randomised element in which patients
eligible for either VSRR or PEARS are invited to have the deci-
sion made by random allocation.
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